RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW

Anjo Sunny, M. Khan, Darpelly Mahesh, N. Chauhan, Ritu Mishra, Namindla Presila, A. Samuel
{"title":"RISK-BENEFIT ANALYSIS AND RISK MINIMIZATION OF QUINAPRIL: A REVIEW","authors":"Anjo Sunny, M. Khan, Darpelly Mahesh, N. Chauhan, Ritu Mishra, Namindla Presila, A. Samuel","doi":"10.3844/AJPTSP.2014.68.74","DOIUrl":null,"url":null,"abstract":"The purpose of this review is to give the readers a n insight about the risks and benefits of ‘quinapri l’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, a n attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day cli nical practice.","PeriodicalId":7769,"journal":{"name":"American Journal of Pharmacology and Toxicology","volume":"17 1","pages":"68-74"},"PeriodicalIF":0.0000,"publicationDate":"2014-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Pharmacology and Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3844/AJPTSP.2014.68.74","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The purpose of this review is to give the readers a n insight about the risks and benefits of ‘quinapri l’, a potent Angiotensin Converting Enzyme Inhibitor (ACEI). Quinapril is a highly effective novel drug indicated for treatment of congestive heart failure and hypertension. Despite of the fact that safety profile is quite well with low incidence of adverse effects, a n attempt has been made to minimize the risks and subsequently minimizing the adverse consequences of this competitive inhibitor, thereby increasing the benefits of this enzyme inhibitor in day to day cli nical practice.
喹普利的风险-收益分析和风险最小化:综述
这篇综述的目的是让读者了解“喹那普利1”的风险和益处,一种有效的血管紧张素转换酶抑制剂(ACEI)。喹普利是一种治疗充血性心力衰竭和高血压的高效新药。尽管该酶抑制剂具有良好的安全性和较低的不良反应发生率,但人们仍在努力将其风险和不良后果降至最低,从而在日常临床实践中增加该酶抑制剂的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信